Advances in nucleoside monophosphate prodrugs as anti-HCV agents.
Nucleoside monophosphate prodrugs that are eventually bioconverted to the active nucleoside triphosphate (NTP) offer the potential to deliver increased intracellular NTP levels and/or organ-specific NTP enhancement. There are several classes of monophosphate prodrugs that have been applied to HCV drug discovery, and some of these approaches are currently being evaluated in humans. This review discusses recent advances in monophosphate prodrug approaches to improve oral absorption, stability and pharmacokinetic profile, including their advantages and potential pitfalls.
RFS Pharma LLC, Tucker, GA, USA.
Drew R
DR
Bobeck
Raymond F
RF
Schinazi
Steven J
SJ
Coats
D000284:Administration, Oral; D000998:Antiviral Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D015195:Drug Design; D004341:Drug Evaluation; D016174:Hepacivirus / Q000187:drug effects; D022781:Hepatocytes; D006801:Humans; D008099:Liver / Q000187:drug effects / Q000503:physiopathology; D009705:Nucleosides / Q000008:administration & dosage / Q000493:pharmacokinetics*; D011355:Prodrugs / Q000737:chemistry / Q000493:pharmacokinetics*
D000998:Antiviral Agents; D009705:Nucleosides; D011355:Prodrugs